Rallybio (RLYB) Price & Analysis

Compare

356 Followers

RLYB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.22 - $1.24

Previous CloseN/A

Volume36.64K

Average Volume (3M)318.74K

Market Cap

$23.28M

Enterprise Value-$30.53M

Total Cash (Recent Filing)$45.75M

Total Debt (Recent Filing)$58.00K

Price to Earnings (P/E)―

Beta0.91

Next Earnings

Nov 06, 2025

EPS Estimate

-0.21

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.22

Shares Outstanding41,786,472

10 Day Avg. Volume279,952

30 Day Avg. Volume318,737

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.31

Enterprise Value/Revenue-40.12

Enterprise Value/Gross Profit-41.77

Enterprise Value/Ebitda0.71

Forecast

1Y Price Target

$1.00

Price Target Upside92.31% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial StrategyThe recent workforce reduction plan and sale of REV102 interest should provide cash runway into mid-2027.

Pipeline DevelopmentRallybio will now focus its resources on advancing other pipeline programs, notably RLYB116, an inhibitor of complement component 5 (C5) with potential applications in treating complement-related diseases.

Regulatory ApprovalPh2 Study Of '212 In Pregnant Women At Higher Risk For FNAIT received green lights from EU's EMA and UK's MHRA, allowing the start of the trial.

Bears Say

Clinical Trial SetbacksRLYB212 failed to meet the minimum target PK concentration and there is not enough data to accurately dose adjust safely.

EarningsRLYB reported a 2Q25 net loss of $9.7M.

Program DiscontinuationRallybio has announced the discontinuation of its RLYB212 program, which was undergoing development for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Rallybio News

Rallybio completes dosing of first cohort in RLYB116 study

Rallybio (RLYB) announced the completion of dosing of the first cohort in the Phase 1 confirmatory pharmacokinetic/pharmacodynamic study...

8d ago

RLYB

Rallybio receives $12.5M equity milestone payment from Recursion Pharmaceuticals

Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone...

30d ago

RLYB

RXRX

Rallybio Granted Extension for Nasdaq Compliance

Rallybio ( ($RLYB) ) has shared an update. Rallybio Corporation announced that on February 24, 2025, it received...

1M ago

RLYB

Rallybio Corporation Reports Q2 2025 Financial Results

Rallybio Corporation ( ($RLYB) ) has released its Q2 earnings. Here is a breakdown of the information Rallybio...

2M ago

RLYB

Rallybio’s RLYB116 Study: A Potential Game-Changer in Complement Inhibition

Rallybio Corporation (($RLYB)) announced an update on their ongoing clinical study. Rallybio Corporation is conducting a clinical study...

2M ago

RLYB

Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement

Rallybio stock soared on Tuesday after the company reached an agreement with Recursion Pharmaceuticals. ...

3M ago

RLYB

RXRX

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

It’s time to dive into the biggest stock market stories on Tuesday with TipRanks’ daily wrap-up. ...

3M ago

APP

Rallybio Sells REV102 Program to Recursion Pharmaceuticals

An announcement from Rallybio ( ($RLYB) ) is now available. On July 8, 2025, Rallybio Corporation announced the...

3M ago

RLYB

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an...

3M ago

RLYB

RXRX

Recursion Pharmaceuticals acquires full rights to hypophosphatasia drug REV102

Recursion (RXRX) acquired Rallybio’s (RLYB) full interest in their joint ENPP1 inhibitor program, REV102, and an associated backup...

3M ago

RLYB

RXRX

Rallybio Finalizes Employment Agreement with CMO

Rallybio ( ($RLYB) ) just unveiled an update. On June 25, 2025, Rallybio Corporation formalized an employment agreement...

3M ago

RLYB

Rallybio’s FNAIT Study: A Closer Look at HPA-1a Alloimmunization

Rallybio Corporation (($RLYB)) announced an update on their ongoing clinical study. Rallybio Corporation is conducting a study titled...

3M ago

RLYB

Rallybio’s Phase 2 Study on RLYB212: A Potential Game-Changer for Pregnant Women at Risk

Rallybio Corporation (($RLYB)) announced an update on their ongoing clinical study. Rallybio Corporation is conducting a Phase 2...

3M ago

RLYB

Rallybio initiates dosing in RLYB116 study

Rallybio (RLYB) announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic study evaluating RLYB116, the company’s...

4M ago

RLYB

RLYB FAQ

What was Rallybio’s price range in the past 12 months?

Rallybio lowest stock price was $0.22 and its highest was $1.24 in the past 12 months.

What is Rallybio’s market cap?

Rallybio’s market cap is $23.28M.

When is Rallybio’s upcoming earnings report date?

Rallybio’s upcoming earnings report date is Nov 06, 2025 which is in 34 days.

How were Rallybio’s earnings last quarter?

Rallybio released its earnings results on Aug 07, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.245 by $0.025.

Is Rallybio overvalued?

According to Wall Street analysts Rallybio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Rallybio pay dividends?

Rallybio does not currently pay dividends.

What is Rallybio’s EPS estimate?

Rallybio’s EPS estimate is -0.21.

How many shares outstanding does Rallybio have?

Rallybio has 41,786,472 shares outstanding.

What happened to Rallybio’s price movement after its last earnings report?

Rallybio reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.245. Following the earnings report the stock price went down -3.774%.

Which hedge fund is a major shareholder of Rallybio?

Currently, no hedge funds are holding shares in RLYB

Rallybio Stock Smart Score

Neutral

Fundamentals

Return on Equity

-66.12%

Trailing 12-Months

Asset Growth

-44.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rallybio

Rallybio (RLYB) is a biotechnology company focused on identifying and developing transformative therapies for patients with severe and rare disorders. The company operates within the biopharmaceutical sector, leveraging cutting-edge science and innovative research to address unmet medical needs. Rallybio's core products and services include the development of novel therapeutics in areas such as hematology, immunology, and metabolic disorders.

Rallybio (RLYB) Earnings & Revenues

Historic Earnings Reports

RLYB Stock 12 Month Forecast

Average Price Target

$1.00

▲(92.31% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5753846153846154,0.6107692307692308,0.6461538461538462,0.6815384615384615,0.716923076923077,0.7523076923076923,0.7876923076923077,0.823076923076923,0.8584615384615385,0.8938461538461538,0.9292307692307693,0.9646153846153847,{"y":1,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5753846153846154,0.6107692307692308,0.6461538461538462,0.6815384615384615,0.716923076923077,0.7523076923076923,0.7876923076923077,0.823076923076923,0.8584615384615385,0.8938461538461538,0.9292307692307693,0.9646153846153847,{"y":1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.5753846153846154,0.6107692307692308,0.6461538461538462,0.6815384615384615,0.716923076923077,0.7523076923076923,0.7876923076923077,0.823076923076923,0.8584615384615385,0.8938461538461538,0.9292307692307693,0.9646153846153847,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.9,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.61,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.33,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >